European tech leaders warn against stifling AI innovation as SAP’s CEO pushes back on European Union regulations. At the same time, the FDA rolls out new healthcare AI oversight measures, and major tech companies struggle to meet European compliance standards. Testing reveals that even top AI models from OpenAI, Meta and Anthropic fall short of EU requirements in key areas like cybersecurity and bias prevention, highlighting the growing tension between rapid AI advancement and regulatory control.
SAP CEO Christian Klein reportedly said Tuesday (Oct. 22) that excessive regulation of artificial intelligence in Europe could hamper the region’s competitiveness against global tech powerhouses in the United States and China. His comments came as European policymakers consider implementing comprehensive AI oversight measures.
Klein, who has led Europe’s largest software company since 2020, said during a CNBC interview that he advocated for a focus on AI outcomes rather than blanket technology restrictions.
SAP has recently pivoted toward AI integration while managing a significant restructuring that affects 8,000 employees globally. Klein’s stance reflects growing concern among European tech leaders that regulatory constraints could disadvantage the region’s emerging AI sector, particularly its startup ecosystem, in an increasingly competitive global market.
The European Union has become the first major power to implement comprehensive AI regulation. The new framework introduces strict oversight of high-risk AI systems, requiring transparency and human supervision. While designed to protect citizens’ rights, the move sparks debate over potential impacts on Europe’s technological competitiveness.
The FDA has unveiled sweeping measures to strengthen its oversight of artificial intelligence in healthcare, marking a significant shift in how medical AI tools will be regulated. The agency’s new framework, detailed in a recent JAMA publication, aims to balance rapid technological innovation with patient safety concerns.
Since approving its first AI medical device in 1995, the FDA has greenlit nearly 1,000 AI-based products, primarily in radiology and cardiology. The agency now faces an unprecedented surge in AI submissions, with applications for drug development alone increasing tenfold in the past year.
At the heart of the FDA’s approach is a five-point action plan focused on the lifecycle management of AI products. The strategy emphasizes continuous monitoring of AI systems after deployment, which is crucial for complex tools like large language models that may produce unpredictable outputs in clinical settings.
The agency is adopting a risk-based regulatory framework, applying stricter oversight to critical applications like cardiac defibrillators while maintaining lighter touch regulation for administrative AI tools. International collaboration is prominent in the FDA’s strategy, with the agency working alongside global regulators to establish harmonized standards.
This regulatory evolution comes as AI increasingly penetrates healthcare, from drug discovery to mental health applications, signaling a new era in medical technology governance.
Major artificial intelligence companies face significant hurdles in meeting European Union regulatory requirements, with leading models showing weaknesses in crucial areas like cybersecurity and bias prevention, Reuters reported.
A new compliance testing framework developed by Swiss startup LatticeFlow AI reveals potential vulnerabilities that could expose tech giants to substantial penalties.
The assessment tool, which evaluates AI models against forthcoming EU regulations, found that while companies like Meta, OpenAI and Anthropic achieved generally strong scores, specific shortcomings could prove costly. OpenAI’s GPT-3.5 Turbo scored just 0.46 on discriminatory output measures, while Meta’s Llama 2 received a modest 0.42 for cybersecurity resilience.
Anthropic’s Claude 3 Opus emerged as the top performer, scoring 0.89 overall. However, even high-performing models may require significant adjustments to meet the EU’s comprehensive AI Act, which carries penalties of up to 7% of global annual turnover for non-compliance.
The findings come at a critical time as the EU works to establish enforcement guidelines for its AI regulations by spring 2025. The LatticeFlow framework, welcomed by EU officials as a “first step” in implementing the new laws, offers companies a roadmap for compliance while highlighting the challenges ahead in aligning AI development with regulatory demands.
For all PYMNTS AI coverage, subscribe to the daily AI Newsletter.
We’re always on the lookout for opportunities to partner with innovators and disruptors.
Learn More